The ErbB2-antigen is targetable with vaccines that potentially trigger high levels of antibodies, which, through the mediation of lymphocyte T cells, elicits the suppression of the Th-1 response and T-cell cytotoxic proliferation in overexpressed tumor-antigens [174]. This evidence concerns the gene NELFCD and neoplasm.